![Cheng Liu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cheng Liu
Verkställande Direktör på
ESTRELLA IMMUNOPHARMA, INC.
Förmögenhet: 2 M $ per 2026-05-31
Profil
Dr. Cheng Liu is a President, Chief Executive Officer & Director at Eureka Therapeutics, Inc., a Chairman & Co-Chief Executive Officer at InvisiShield Technologies Ltd., a President, Chief Executive Officer & Director at Estrella Biopharma, Inc. and a President, Chief Executive Officer & Director at Estrella Immunopharma, Inc. He is on the Board of Directors at Eureka Therapeutics, Inc., Estrella Biopharma, Inc. and Estrella Immunopharma, Inc. Dr. Liu was previously employed as a Chairman by JW (Cayman) Therapeutics Co. Ltd., a Member-Adversary & Executive Committee by SAPA-West, and a Principal Scientist by Chiron Corp.
He received his undergraduate degree from Peking University, a graduate degree from Peking University and a doctorate degree from the University of California, Berkeley.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2024-12-31 | 5 764 582 ( 1,38 % ) | 1 M $ | 2026-05-31 | |
| 2026-05-20 | 297 437 ( 0,69 % ) | 324 206 $ | 2026-05-31 |
Aktiva positioner av Cheng Liu
| Företag | Position | Start |
|---|---|---|
| ESTRELLA IMMUNOPHARMA, INC. | Verkställande Direktör | - |
Eureka Therapeutics, Inc.
 Eureka Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops T-cell therapies for cancer patients with solid tumors | Grundare | 2010-01-21 |
InvisiShield Technologies Ltd.
 InvisiShield Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Verkställande Direktör | - |
Estrella Biopharma, Inc.
 Estrella Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces medicines for hematological cancers & tumors | Grundare | - |
Tidigare kända positioner av Cheng Liu
| Företag | Position | Slut |
|---|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Ordförande | 2026-06-26 |
SAPA-West | Företagsledare/Principal | 2007-01-01 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Företagsledare/Principal | - |
Cheng Lius utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
5
Första gradens relationer
9
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 9 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops T-cell therapies for cancer patients with solid tumors | Health Technology |
Peking University
 Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SAPA-West | |
JW (Cayman) Therapeutics Co. Ltd.
 JW (Cayman) Therapeutics Co. Ltd. BiotechnologyHealth Technology Operates as biotechnology company that develops and manufactures cell immunotherapy products | Health Technology |
InvisiShield Technologies Ltd.
InvisiShield Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
Estrella Biopharma, Inc.
Estrella Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces medicines for hematological cancers & tumors | Health Technology |
Estrella Immunopharma, Inc.
 Estrella Immunopharma, Inc. BiotechnologyHealth Technology Operates as a preclinical-stage biopharmaceutical company focusing on cancer therapeutics to address treatment of blood cancers and solid tumors | Health Technology |
